Madaan Priyanka, Jauhari Prashant, Gupta Aparajita, Chakrabarty Biswaroop, Gulati Sheffali
Child Neurology Division, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.
Child Neurology Division, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.
Brain Dev. 2018 Mar;40(3):229-232. doi: 10.1016/j.braindev.2017.09.008. Epub 2017 Oct 14.
Epilepsy of infancy with migrating focal seizures {a.k.a malignant migrating partial seizures of infancy (MMPSI)} is an uncommon epileptic encephalopathy with a poor prognosis. Migrating focal seizures with autonomic features, developmental stagnation and refractoriness to treatment are its key features. It is caused by genetic defects in various ion channels, most common being sodium activated potassium channel (KCNT1), found in up to 50% of cases. With advent of genetic diagnosis and precision medicine, many targeted therapies have been identified. Antagonist of KCNT1 coded ion channel like Quinidine has shown promising results in MMPSI. Here we report first mutation proven case of MMPSI from India. This child had a novel heterozygous missense mutation in exon10 of the KCNT1 gene (chr9:138650308; c.808C > C/G (p.Q270E)) which was pathogenic. Neither quinidine nor ketogenic diet could control his seizures. Ultimately, the child succumbed to his illness at nine months of age.
婴儿期伴游走性局灶性发作的癫痫(又称婴儿期恶性游走性部分性癫痫,MMPSI)是一种罕见的癫痫性脑病,预后不良。具有自主神经特征的游走性局灶性发作、发育停滞和治疗难治性是其主要特征。它由各种离子通道的基因缺陷引起,最常见的是钠激活钾通道(KCNT1),在高达50%的病例中被发现。随着基因诊断和精准医学的出现,已经确定了许多靶向治疗方法。KCNT1编码离子通道的拮抗剂如奎尼丁在MMPSI中显示出有前景的结果。在此我们报告印度首例经突变证实的MMPSI病例。该患儿在KCNT1基因外显子10(chr9:138650308;c.808C > C/G (p.Q270E))有一个新的杂合错义突变,该突变具有致病性。奎尼丁和生酮饮食均无法控制其癫痫发作。最终,患儿在9个月大时因病死亡。